Biomarcadores de las Enfermedades Cardíacas
BIOMARCS
Maastricht University Medical Centre
Maastricht, HolandaPublicaciones en colaboración con investigadores/as de Maastricht University Medical Centre (5)
2024
-
Effects of spironolactone on exercise blood pressure in patients at increased risk of developing heart failure: report from the HOMAGE trial
Hypertension Research
-
Urinary proteomic signature of mineralocorticoid receptor antagonism by spironolactone: evidence from the HOMAGE trial
Heart, Vol. 110, Núm. 19, pp. 1180-1187
2023
-
Evaluation of Microvascular Rarefaction in Vascular Cognitive Impairment and Heart Failure (CRUCIAL): Study Protocol for an Observational Study
Cerebrovascular Diseases Extra, Vol. 13, Núm. 1, pp. 18-32
-
Protein Biomarkers of New-Onset Heart Failure: Insights From the Heart Omics and Ageing Cohort, the Atherosclerosis Risk in Communities Study, and the Framingham Heart Study
Circulation: Heart Failure, Vol. 16, Núm. 5, pp. E009694
2022
-
Biomarker-based assessment of collagen cross-linking identifies patients at risk of heart failure more likely to benefit from spironolactone effects on left atrial remodelling. Insights from the HOMAGE clinical trial
European Journal of Heart Failure, Vol. 24, Núm. 2, pp. 321-331